RE104 Safety and Efficacy Study in Postpartum Depression
Status:
COMPLETED
Trial end date:
2025-06-16
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms in participants with moderate-to-severe postpartum depression (PPD) as compared to active-placebo.